Description: Venetoclax (formerly known as ABT-199 or GDC-0199; Venclexta) is a potent, selective and orally bioavailable small molecule inhibitor of the anti-apoptotic protein BCL-2 (B-cell lymphoma-2) with Ki of<0.01 nM. On April 11, 2016, the FDA approved venetoclax for use in patients with chronic lymphocytic leukemia (CLL) who have 17p deletion (deletion located on the chromosome 17 short arm) and who have been treated with at least one prior therapy. The mechanism of action of venetoclax is to mimic BH3 (the native ligand of BCL-2) and act as a BCL-2 inhibitor. It blocks the anti-apoptotic BCL-2 protein, leading to programmed cell death of CLL cells.
References: Haematologica. 2017 Apr;102(4):755-764; Souers AJ, et al. Nat Med, 2013, 19(2), 202-208.
Publications Citing Use of InvivoChem Venetoclax (ABT-199; GDC-0199):
[1] Seiller et al. Cell Death and Disease ( 2020) 11:316.
[2] VCP/p97 inhibitor for the treatment of cancer. WO 2021/231323 A1